1. Academic Validation
  2. Automated Assays to Identify Modulators of Transcription Factor EB Translocation and Autophagy

Automated Assays to Identify Modulators of Transcription Factor EB Translocation and Autophagy

  • Assay Drug Dev Technol. 2022 Feb-Mar;20(2):67-74. doi: 10.1089/adt.2021.119.
Anaelle da Costa 1 Christèle Picoli 1 Franck Mouthon 1 Mathieu Charvériat 1
Affiliations

Affiliation

  • 1 Theranexus, R&D Department, Lyon, France.
Abstract

Autophagy is a process leading to the degradation of cellular material, in organelles called lysosomes, to supply energy or generate building blocks for the synthesis of new Materials. Over the past decades, its role has been evidenced in several indications, notably in neurodegenerative disorders and orphan diseases called lysosomal storage disorders and its modulation is largely envisioned as a therapeutic avenue to alleviate the symptoms and reverse the clinical courses of these indications. Identifying new chemical classes and drugs is, hence, of huge importance. In this study, we developed automated assays to assess the potential efficacy of chemical compounds on different steps of Autophagy, notably its induction through the localization of a largely involved transcription factor, transcription factor EB (TFEB). These assays were then used to screen a collection of 1,520 approved drugs. This study led to the identification of five candidate hits modulating Autophagy and TFEB subcellular localization. Our results suggest the repurposing potential of already approved drugs in central nervous system disorders with lysosomal storage impairments.

Keywords

LC3; TFEB; autophagy; lysosome.

Figures
Products